Published in Cancer Res on February 09, 2010
A reverse binding motif that contributes to specific protease inhibition by antibodies. J Mol Biol (2011) 0.91
Targeting uPAR with antagonistic recombinant human antibodies in aggressive breast cancer. Cancer Res (2013) 0.91
Fluorescent imaging of cancerous tissues for targeted surgery. Adv Drug Deliv Rev (2014) 0.90
Imaging a functional tumorigenic biomarker in the transformed epithelium. Proc Natl Acad Sci U S A (2012) 0.86
Targeting zymogen activation to control the matriptase-prostasin proteolytic cascade. J Med Chem (2011) 0.84
Diversity of matriptase expression level and function in breast cancer. PLoS One (2012) 0.84
Peptide length and leaving-group sterics influence potency of peptide phosphonate protease inhibitors. Chem Biol (2011) 0.81
Human cancer cells retain modest levels of enzymatically active matriptase only in extracellular milieu following induction of zymogen activation. PLoS One (2014) 0.79
Protein analytical assays for diagnosing, monitoring, and choosing treatment for cancer patients. J Healthc Eng (2012) 0.79
Detection of active matriptase using a biotinylated chloromethyl ketone peptide. PLoS One (2013) 0.78
Proteinase-activated receptor 2 (PAR2) decreases apoptosis in colonic epithelial cells. J Biol Chem (2014) 0.78
Type II transmembrane serine proteases as potential targets for cancer therapy. Biol Chem (2016) 0.76
Matriptase shedding is closely coupled with matriptase zymogen activation and requires de novo proteolytic cleavage likely involving its own activity. PLoS One (2017) 0.75
Matriptase induces metalloproteinase-dependent aggrecanolysis in vitro and in vivo: multiple mechanisms promote cartilage damage in osteoarthritis. Arthritis Rheumatol (2017) 0.75
New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer (2002) 24.71
In vivo imaging of tumors with protease-activated near-infrared fluorescent probes. Nat Biotechnol (1999) 8.46
Arming antibodies: prospects and challenges for immunoconjugates. Nat Biotechnol (2005) 5.80
Tumor imaging by means of proteolytic activation of cell-penetrating peptides. Proc Natl Acad Sci U S A (2004) 4.95
Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis. Cancer Cell (2004) 4.38
Biology and biochemistry of proteinases in tumor invasion. Physiol Rev (1993) 4.17
The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci (2000) 3.91
Imaging tri-fusion multimodality reporter gene expression in living subjects. Cancer Res (2004) 3.16
Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody. Proc Natl Acad Sci U S A (2002) 3.16
Noninvasive optical imaging of cysteine protease activity using fluorescently quenched activity-based probes. Nat Chem Biol (2007) 2.80
Reverse biochemistry: use of macromolecular protease inhibitors to dissect complex biological processes and identify a membrane-type serine protease in epithelial cancer and normal tissue. Proc Natl Acad Sci U S A (1999) 2.01
The progress and promise of molecular imaging probes in oncologic drug development. Clin Cancer Res (2005) 1.97
Cysteine cathepsins in human cancer. Biol Chem (2004) 1.91
Gene expression profiling identifies matriptase overexpression in malignant mesothelioma. Chest (2004) 1.89
The hepatocyte growth factor regulatory factors in human breast cancer. Clin Cancer Res (2004) 1.80
The macrophage-stimulating protein pathway promotes metastasis in a mouse model for breast cancer and predicts poor prognosis in humans. Proc Natl Acad Sci U S A (2007) 1.79
Type II transmembrane serine proteases. J Biol Chem (2009) 1.77
Molecular cloning of cDNA for matriptase, a matrix-degrading serine protease with trypsin-like activity. J Biol Chem (1999) 1.62
Coordinate expression and functional profiling identify an extracellular proteolytic signaling pathway. Proc Natl Acad Sci U S A (2007) 1.52
Identification of degradome components associated with prostate cancer progression by expression analysis of human prostatic tissues. Br J Cancer (2005) 1.45
Expression of the serine protease matriptase and its inhibitor HAI-1 in epithelial ovarian cancer: correlation with clinical outcome and tumor clinicopathological parameters. Clin Cancer Res (2002) 1.44
Matriptase and its putative role in cancer. Cell Mol Life Sci (2006) 1.44
A novel biomarker for staging human prostate adenocarcinoma: overexpression of matriptase with concomitant loss of its inhibitor, hepatocyte growth factor activator inhibitor-1. Cancer Epidemiol Biomarkers Prev (2006) 1.41
Characterization of a novel, membrane-bound, 80-kDa matrix-degrading protease from human breast cancer cells. Monoclonal antibody production, isolation, and localization. J Biol Chem (1997) 1.36
Identification and characterization of a novel matrix-degrading protease from hormone-dependent human breast cancer cells. Cancer Res (1993) 1.14
Potent and selective inhibition of membrane-type serine protease 1 by human single-chain antibodies. Biochemistry (2003) 1.12
The mechanism of inhibition of antibody-based inhibitors of membrane-type serine protease 1 (MT-SP1). J Mol Biol (2007) 1.10
Structure of an Fab-protease complex reveals a highly specific non-canonical mechanism of inhibition. J Mol Biol (2008) 1.09
Hepatocyte growth factor activator inhibitor-1 has a complex subcellular itinerary. Biochem J (2008) 1.02
Quantitation of membrane type serine protease 1 (MT-SP1) in transformed and normal cells. Biol Chem (2003) 0.98
Roles of functional and structural domains of hepatocyte growth factor activator inhibitor type 1 in the inhibition of matriptase. J Biol Chem (2007) 0.98
MT-SP1 proteolysis and regulation of cell-microenvironment interactions. Front Biosci (2008) 0.96
Expression of EMMPRIN and matriptase in esophageal squamous cell carcinoma: correlation with clinicopathological parameters. Dis Esophagus (2006) 0.94
Noninvasive imaging of molecular events with bioluminescent reporter genes in living subjects. Methods Mol Biol (2007) 0.90
Matriptase and survivin expression associated with tumor progression and malignant potential in breast cancer of Chinese women: tissue microarray analysis of immunostaining scores with clinicopathological parameters. Dis Markers (2008) 0.88
Expression of serine protease matriptase in renal cell carcinoma: correlation of tissue microarray immunohistochemical expression analysis results with clinicopathological parameters. Int J Surg Pathol (2006) 0.88
Increasing expression of serine protease matriptase in ovarian tumors: tissue microarray analysis of immunostaining score with clinicopathological parameters. Mod Pathol (2006) 0.85
Decreased matriptase/HAI-1 ratio in advanced colorectal adenocarcinoma of Chinese patients. Chin J Physiol (2007) 0.77
Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res (2006) 4.43
Global landscape of HIV-human protein complexes. Nature (2011) 3.70
Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin Cancer Res (2002) 3.14
Vif hijacks CBF-β to degrade APOBEC3G and promote HIV-1 infection. Nature (2011) 2.71
Molecular evolution of antibody cross-reactivity for two subtypes of type A botulinum neurotoxin. Nat Biotechnol (2006) 2.66
Analysis of the neurotoxin complex genes in Clostridium botulinum A1-A4 and B1 strains: BoNT/A3, /Ba4 and /B1 clusters are located within plasmids. PLoS One (2007) 2.28
Local protease signaling contributes to neural tube closure in the mouse embryo. Dev Cell (2010) 2.19
Substrate profiling of cysteine proteases using a combinatorial peptide library identifies functionally unique specificities. J Biol Chem (2006) 2.05
A single treatment of yttrium-90-labeled CHX-A"-C6.5 diabody inhibits the growth of established human tumor xenografts in immunodeficient mice. Cancer Res (2004) 2.00
Trapping moving targets with small molecules. Science (2009) 1.86
Mycobacterium tuberculosis MycP1 protease plays a dual role in regulation of ESX-1 secretion and virulence. Cell Host Microbe (2010) 1.76
Antibodies from phage antibody libraries. J Immunol Methods (2004) 1.75
Engineering of a macromolecular scaffold to develop specific protease inhibitors. Nat Biotechnol (2003) 1.73
Genetic and immunological comparison of anti-botulinum type A antibodies from immune and non-immune human phage libraries. Vaccine (2002) 1.69
Adhesion signaling by a novel mitotic substrate of src kinases. Oncogene (2005) 1.68
Influence of affinity and antigen internalization on the uptake and penetration of Anti-HER2 antibodies in solid tumors. Cancer Res (2011) 1.62
Generation and characterization of a protective monoclonal antibody to Pseudomonas aeruginosa PcrV. J Infect Dis (2002) 1.61
A structural perspective of the sequence variability within botulinum neurotoxin subtypes A1-A4. J Mol Biol (2006) 1.59
Coordinate expression and functional profiling identify an extracellular proteolytic signaling pathway. Proc Natl Acad Sci U S A (2007) 1.52
Hepatocyte growth factor is a preferred in vitro substrate for human hepsin, a membrane-anchored serine protease implicated in prostate and ovarian cancers. Biochem J (2005) 1.51
Development of ligand-targeted liposomes for cancer therapy. Expert Opin Ther Targets (2004) 1.48
Impact of single-chain Fv antibody fragment affinity on nanoparticle targeting of epidermal growth factor receptor-expressing tumor cells. J Mol Biol (2007) 1.48
Antibody protection against botulinum neurotoxin intoxication in mice. Infect Immun (2009) 1.43
Plasminogen activation independent of uPA and tPA maintains wound healing in gene-deficient mice. EMBO J (2006) 1.42
Interference with heme binding to histidine-rich protein-2 as an antimalarial strategy. Chem Biol (2002) 1.42
A multi-enzyme cascade of hemoglobin proteolysis in the intestine of blood-feeding hookworms. J Biol Chem (2004) 1.41
Quantitative immuno-positron emission tomography imaging of HER2-positive tumor xenografts with an iodine-124 labeled anti-HER2 diabody. Cancer Res (2005) 1.38
Extraction and inhibition of enzymatic activity of botulinum neurotoxins/A1, /A2, and /A3 by a panel of monoclonal anti-BoNT/A antibodies. PLoS One (2009) 1.35
Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells. Cancer Res (2003) 1.33
Regulation of antibody-dependent cellular cytotoxicity by IgG intrinsic and apparent affinity for target antigen. J Immunol (2007) 1.32
Therapeutic antibodies: current state and future trends--is a paradigm change coming soon? Methods Mol Biol (2009) 1.32
Specificity profiling of seven human tissue kallikreins reveals individual subsite preferences. J Biol Chem (2006) 1.31
Catalytic properties and inhibition of proline-specific dipeptidyl peptidases II, IV and VII. Biochem J (2003) 1.29
Extraction of BoNT/A, /B, /E, and /F with a single, high affinity monoclonal antibody for detection of botulinum neurotoxin by Endopep-MS. PLoS One (2010) 1.28
Expedient solid-phase synthesis of fluorogenic protease substrates using the 7-amino-4-carbamoylmethylcoumarin (ACC) fluorophore. J Org Chem (2002) 1.26
Avidity-mediated enhancement of in vivo tumor targeting by single-chain Fv dimers. Clin Cancer Res (2006) 1.26
Mouse and human lung fibroblasts regulate dendritic cell trafficking, airway inflammation, and fibrosis through integrin αvβ8-mediated activation of TGF-β. J Clin Invest (2011) 1.25
Fabs enable single particle cryoEM studies of small proteins. Structure (2012) 1.25
Continuous imaging of plasmon rulers in live cells reveals early-stage caspase-3 activation at the single-molecule level. Proc Natl Acad Sci U S A (2009) 1.25
Mapping tumor epitope space by direct selection of single-chain Fv antibody libraries on prostate cancer cells. Cancer Res (2004) 1.25
Methyl groups as probes for proteins and complexes in in-cell NMR experiments. J Am Chem Soc (2004) 1.23
Cercarial elastase is encoded by a functionally conserved gene family across multiple species of schistosomes. J Biol Chem (2002) 1.22
Anti-CD166 single chain antibody-mediated intracellular delivery of liposomal drugs to prostate cancer cells. Mol Cancer Ther (2007) 1.22
Elimination of 13Calpha splitting in protein NMR spectra by deconvolution with maximum entropy reconstruction. J Am Chem Soc (2003) 1.21
Inhibition of a viral enzyme by a small-molecule dimer disruptor. Nat Chem Biol (2009) 1.21
Structural and functional relationships in the virulence-associated cathepsin L proteases of the parasitic liver fluke, Fasciola hepatica. J Biol Chem (2007) 1.19
Vinyl sulfones as antiparasitic agents and a structural basis for drug design. J Biol Chem (2009) 1.18
Phage versus phagemid libraries for generation of human monoclonal antibodies. J Mol Biol (2002) 1.18
Isotope-coded and affinity-tagged cross-linking (ICATXL): an efficient strategy to probe protein interaction surfaces. J Am Chem Soc (2006) 1.17
Altered substrate specificity of drug-resistant human immunodeficiency virus type 1 protease. J Virol (2002) 1.17
Granzyme B proteolyzes receptors important to proliferation and survival, tipping the balance toward apoptosis. J Biol Chem (2006) 1.16
Global identification of peptidase specificity by multiplex substrate profiling. Nat Methods (2012) 1.14
Potent and selective inhibition of membrane-type serine protease 1 by human single-chain antibodies. Biochemistry (2003) 1.12
Selective chemical functional probes of granzymes A and B reveal granzyme B is a major effector of natural killer cell-mediated lysis of target cells. Chem Biol (2005) 1.12
Affinity thresholds for membrane fusion triggering by viral glycoproteins. J Virol (2007) 1.11
Quantitative identification of the protonation state of histidines in vitro and in vivo. Biochemistry (2003) 1.11
Selective inhibition of the collagenolytic activity of human cathepsin K by altering its S2 subsite specificity. Biochemistry (2002) 1.10
A single-domain llama antibody potently inhibits the enzymatic activity of botulinum neurotoxin by binding to the non-catalytic alpha-exosite binding region. J Mol Biol (2010) 1.10
The mechanism of inhibition of antibody-based inhibitors of membrane-type serine protease 1 (MT-SP1). J Mol Biol (2007) 1.10
Structure of an Fab-protease complex reveals a highly specific non-canonical mechanism of inhibition. J Mol Biol (2008) 1.09
Therapeutic efficacy of anti-ErbB2 immunoliposomes targeted by a phage antibody selected for cellular endocytosis. Biochim Biophys Acta (2002) 1.08
The intracellular antibody capture technology (IACT): towards a consensus sequence for intracellular antibodies. J Mol Biol (2002) 1.08
Identification and characterization of tumor antigens by using antibody phage display and intrabody strategies. Mol Immunol (2007) 1.07
Isolation of scFvs to in vitro produced extracellular domains of EGFR family members. Cancer Biother Radiopharm (2005) 1.06
A parasite cysteine protease is key to host protein degradation and iron acquisition. J Biol Chem (2008) 1.06
Preclinical manufacture of anti-HER2 liposome-inserting, scFv-PEG-lipid conjugate. 2. Conjugate micelle identity, purity, stability, and potency analysis. Biotechnol Prog (2005) 1.06
An affinity matured minibody for PET imaging of prostate stem cell antigen (PSCA)-expressing tumors. Eur J Nucl Med Mol Imaging (2010) 1.05
The periplasmic serine protease inhibitor ecotin protects bacteria against neutrophil elastase. Biochem J (2004) 1.05
Towards proteome-wide production of monoclonal antibody by phage display. J Mol Biol (2002) 1.05
Antagonistic anti-urokinase plasminogen activator receptor (uPAR) antibodies significantly inhibit uPAR-mediated cellular signaling and migration. J Biol Chem (2010) 1.04
Prediction of protease substrates using sequence and structure features. Bioinformatics (2010) 1.04
The oligomeric structure of human granzyme A is a determinant of its extended substrate specificity. Nat Struct Biol (2003) 1.04
Communication between the active sites and dimer interface of a herpesvirus protease revealed by a transition-state inhibitor. Proc Natl Acad Sci U S A (2004) 1.03
GPS-Prot: a web-based visualization platform for integrating host-pathogen interaction data. BMC Bioinformatics (2011) 1.03
A novel Entamoeba histolytica cysteine proteinase, EhCP4, is key for invasive amebiasis and a therapeutic target. J Biol Chem (2010) 1.03
Critical role of amino acid 23 in mediating activity and specificity of vinckepain-2, a papain-family cysteine protease of rodent malaria parasites. Biochem J (2002) 1.02
Hemoglobin cleavage site-specificity of the Plasmodium falciparum cysteine proteases falcipain-2 and falcipain-3. PLoS One (2009) 1.02
IrAE: an asparaginyl endopeptidase (legumain) in the gut of the hard tick Ixodes ricinus. Int J Parasitol (2007) 1.01
Using phage display to select antibodies recognizing post-translational modifications independently of sequence context. Mol Cell Proteomics (2006) 1.00
Global substrate profiling of proteases in human neutrophil extracellular traps reveals consensus motif predominantly contributed by elastase. PLoS One (2013) 1.00
Substrates of the prostate-specific serine protease prostase/KLK4 defined by positional-scanning peptide libraries. Prostate (2005) 0.99
Structures and specificity of the human kallikrein-related peptidases KLK 4, 5, 6, and 7. Biol Chem (2008) 0.99
Papa's got a brand new tag: advances in identification of proteases and their substrates. Trends Biotechnol (2005) 0.99
Yeast mating for combinatorial Fab library generation and surface display. FEBS Lett (2004) 0.99